In the article “German Biotechnology Start-ups 2020 – Status and Perspectives” by Dr. Michael Thiel, the status of German biotechnology in 2020 is presented on the one hand, and on the other hand the article aims to provide food for thought on what should change in the future to make Germany more attractive as a research location for biotechnology. You can read the entire German article here

On October 22nd, Dr. Michael Thiel will give feedback as an expert at the Fundraising Day of Forum MedTech Pharma e.V. Life Science Start Ups on the optimization of the business plan, P/L, cash flow planning, optimization of the fundraising strategy and, if necessary, the addition to the investor list. Life Science Start Ups from the target group will be given the opportunity to discuss their specific questions about business planning and financing of their start up and to get feedback from an expert. Further information on the expert consultation day on fundraising can be found here

Sonja Terszowski is a reviewer in this year’s business plan competition for the medical industry. Here, innovative business ideas from the medical and healthcare industry have the chance to put their medical business concepts in a future-proof starting position. The aim of the competition is to promote the establishment and settlement of innovative companies in the medical and health care industry. The award ceremony including jury meeting will take place on November 17, 2020. Further information on the business plan competition medical industry can be found at

The Munich-based company GNA Biosolutions, which was already supported by SANEMUS AG in the Series C financing round in August 2019, has developed a particularly rapid Covid-19 test, which is to be launched on the market in June at the latest.

The GNA Covid-19 system will consist of a portable testing device which can detect coronavirus for up to 8 samples at a time, in 15 minutes or less.

The tests and system will be provided to first responders and laboratories and can also be used in drive through testing sites. Anticipated availability for the first systems and tests is 8-12 weeks.

You can find the complete article of the Süddeutsche Zeitung here

More information about GNA Biosolutions can be found here

The theme for 11th October 2019 is Corporate Governance – Who controls the supervisory board?

Ideas and inspiration will be provided by Daniela Bergdolt, Vice President of Deutsche Schutzvereinigung für Wertpapierbesitz e.V., Düsseldorf, and Prälat Dr. Lorenz Wolf, Chairman of the Chairman’s Conference of the Boards (Supervisory Board) of ARD, Munich.

In addition, Dr. Joachim Faber, Chairman of the Supervisory Board of Deutsche Börse AG, Frankfurt am Main, will bid farewell to the participants with a dinner speech.

Detailed information on the event can be found at

The SANEMUS team has successfully supported the German Diagnostics Start-up GNA Biosolutions GmbH in its series C financing round. In the end 13.5 M$ were raised from well-known investors. Further information can be found in the press release 



SANEMUS supports a biotech start-up in fundraising. The start-up focusses on diabetic complications and is currently developing the first causal, anti-infalmmatory treatment of diabetic nephropathy. 

If you are interested in an investment, please contact us. 


Dr. Michael Thiel publishes Part III of the three-part series on venture capital in the German life-science-industry for the journal pharmind. The focus is on the consideration of institutional venture-capital-funds, which are the largest and most important investors for life science start-ups. An overview of selected European and German life science venture-capital-funds should clarify the backlog for venture capital in Germany. Finally, the investment strategies of the funds and investment opportunities for interested investors are presented.

You can find the whole article here  (German-language link)

Dr. Michael Thiel published the second part of the three-part series on venture capital in the German life-science-industry. The article focuses on the role of life-science-corporate-venture-fonds for the innovation strategy of pharma and biotechnology companies. Moreover the motivation of corporate-venture-fonds for their investments and the differences in contrast to institutional venture-capital-fonds are discussed.

You can find the whole article here → (German-language link)

SANEMUS supports a German biotech start-up in searching venture capital. With its innovative, patented compound, the company offers a completely new therapeutic approach for the treatment of HIV patients who are resistant to therapy. Initial talks with institutional VCs have already been started. If you are interested in participating, please contact us.